AR083586A1 - Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico - Google Patents

Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico

Info

Publication number
AR083586A1
AR083586A1 ARP110103988A ARP110103988A AR083586A1 AR 083586 A1 AR083586 A1 AR 083586A1 AR P110103988 A ARP110103988 A AR P110103988A AR P110103988 A ARP110103988 A AR P110103988A AR 083586 A1 AR083586 A1 AR 083586A1
Authority
AR
Argentina
Prior art keywords
acid sequence
amino acid
fviii
amino acids
immune tolerance
Prior art date
Application number
ARP110103988A
Other languages
English (en)
Spanish (es)
Inventor
Hartmut Ehrlich
Katharina Nora Steinitz
Helden Paula Maria Wilhelmina Van
Birgit Maria Reipert
Hans-Peter Schwarz
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR083586A1 publication Critical patent/AR083586A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
ARP110103988A 2010-10-27 2011-10-28 Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico AR083586A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
AR083586A1 true AR083586A1 (es) 2013-03-06

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103988A AR083586A1 (es) 2010-10-27 2011-10-28 Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico

Country Status (20)

Country Link
US (3) US8969524B2 (enExample)
EP (2) EP3260132B1 (enExample)
JP (2) JP6122780B2 (enExample)
KR (2) KR102222864B1 (enExample)
CN (2) CN103298482B (enExample)
AR (1) AR083586A1 (enExample)
AU (2) AU2011319747C1 (enExample)
BR (1) BR112013010362A2 (enExample)
CA (1) CA2815239C (enExample)
DK (1) DK2632479T3 (enExample)
EA (1) EA034494B1 (enExample)
ES (2) ES2639039T3 (enExample)
HK (1) HK1215442A1 (enExample)
MX (1) MX347805B (enExample)
NZ (2) NZ703514A (enExample)
PL (2) PL2632479T3 (enExample)
PT (1) PT2632479T (enExample)
SG (2) SG189914A1 (enExample)
TW (3) TWI580430B (enExample)
WO (1) WO2012058480A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
WO2017180807A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regiment
US20170128544A1 (en) * 2014-06-12 2017-05-11 University Of Hawaii Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity
WO2016120218A1 (en) * 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087161A1 (en) 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
ATE427499T1 (de) * 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations

Also Published As

Publication number Publication date
ES2912455T3 (es) 2022-05-26
JP6122780B2 (ja) 2017-04-26
AU2011319747C1 (en) 2016-07-14
TW201708251A (zh) 2017-03-01
EP3260132B1 (en) 2022-02-09
PL2632479T3 (pl) 2017-09-29
US20120135019A1 (en) 2012-05-31
MX2013004753A (es) 2013-09-13
SG189914A1 (en) 2013-06-28
NZ703514A (en) 2017-02-24
JP2014505014A (ja) 2014-02-27
EA201390617A1 (ru) 2013-10-30
CA2815239A1 (en) 2012-05-03
US9512198B2 (en) 2016-12-06
HK1215442A1 (zh) 2016-08-26
SG10201600656WA (en) 2016-02-26
MX347805B (es) 2017-05-15
AU2011319747B2 (en) 2016-01-07
AU2011319747A1 (en) 2013-05-02
CA2815239C (en) 2019-02-26
CN103298482A (zh) 2013-09-11
CN104926947A (zh) 2015-09-23
TW201231065A (en) 2012-08-01
US20150203567A1 (en) 2015-07-23
TWI580430B (zh) 2017-05-01
AU2016202155B2 (en) 2018-02-01
PL3260132T3 (pl) 2022-08-08
KR102222864B1 (ko) 2021-03-04
AU2016202155A1 (en) 2016-04-28
EA034494B1 (ru) 2020-02-13
CN103298482B (zh) 2015-08-19
KR20190126189A (ko) 2019-11-08
WO2012058480A1 (en) 2012-05-03
US8969524B2 (en) 2015-03-03
TW201730205A (zh) 2017-09-01
EP2632479B1 (en) 2017-06-14
US20170267743A1 (en) 2017-09-21
BR112013010362A2 (pt) 2016-08-02
DK2632479T3 (en) 2017-08-07
PT2632479T (pt) 2017-07-24
KR20130128404A (ko) 2013-11-26
EP3260132A1 (en) 2017-12-27
JP2017095463A (ja) 2017-06-01
KR102040867B1 (ko) 2019-11-07
NZ609474A (en) 2015-06-26
ES2639039T3 (es) 2017-10-25
EP2632479A1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
ES2533874T3 (es) Armazón proteico
AR087091A1 (es) Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
HRP20211010T1 (hr) Kimerni i hibridni polipeptidi faktora viii-fc i postupci njihove upotrebe
ES2661500T3 (es) Variantes de HMGB1 y sus usos
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
IN2014DN10288A (enExample)
CL2020001262A1 (es) Plataforma de presentación en endosporas basadas en paenibacillus, productos y métodos relacionados.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
ES2673556T3 (es) Vacunas para el VHS-2
PE20091931A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
MX2012002216A (es) Nueva endolisina obpgplys.
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
AR086360A1 (es) Polipeptidos anticuerpos que antagonizan cd40
RU2015118580A (ru) НОВЫЙ ВЫСОКО ФУНКЦИОНАЛЬНЫЙ ФЕРМЕНТ, ИМЕЮЩИЙ МОДИФИЦИРОВАННУЮ СУБСТРАТНУЮ СПЕЦИФИЧНОСТЬ β-ГЕКСОЗАМИНИДАЗЫ ЧЕЛОВЕКА И ПРОЯВЛЯЮЩИЙ УСТОЙЧИВОСТЬ К ПРОТЕАЗЕ
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
EA201590611A1 (ru) Новые молекулы, связывающие il-17a, и их медицинское применение
RU2010110545A (ru) Cdh3-пептид и включающее его лекарственное средство
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
RU2019126232A (ru) Пептиды и способы для лечения диабета
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения

Legal Events

Date Code Title Description
FC Refusal